EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Orexin-2 Receptor Agonists in Narcolepsy: Restoring the Missing Signal

Yahya A Alzahrani, Maan H Harbi iD

Journal of Clinical Medicine · 06.11.2026 · 15 (21) · 8642

DOI: 10.3390/jcm15218642 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 06.11.2026. Verfasst von Yahya A Alzahrani und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, King Abdulaziz University, Rabigh 25732, Saudi Arabia. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Narcolepsy type 1 (NT1) results from loss of hypothalamic orexin neurons. Selective orexin-2 receptor (OX2R) agonists now permit direct receptor-level restoration of deficient signaling, but recent broad reviews do not fully integrate the post-approval, trial-specific efficacy, prescribing, and safety evidence. This review asks what benefits and risks are supported by current data, which toxicities appear class-related versus molecule-specific, and how OX2R agonism should be positioned clinically.

Methods

We performed a targeted narrative review of peer-reviewed human studies, major guidelines, trial registries, and regulatory documents updated through 16 October 2026. Peer-reviewed trials and regulatory sources were prioritized; conference- or sponsor-reported data were used only when peer-reviewed evidence was unavailable and were identified as provisional.

Results

In the pivotal phase 3 trials, oveporexton produced placebo-adjusted improvements in MWT sleep latency of 13.8–20.1 min, ESS reductions of 8.0–9.8 points, and weekly cataplexy incidence-rate ratios of 0.25–0.38. Clinically important safety considerations include insomnia, urinary frequency/urgency, CPK elevations, CYP3A interactions, and measurable abuse potential. Alixorexton phase 2 data support OX2R agonism as a developing drug class, whereas firazorexton illustrates molecule-specific hepatotoxic risk.

Conclusions

OX2R agonists are best described as mechanism-based pharmacological restoration of orexin signaling, not proven disease-modifying therapy. Their comparative clinical position remains uncertain because head-to-head trials with established therapies are lacking.

Schlagwörter

Stichwörter der Autor:innen

OX2R agonistcataplexyexcessive daytime sleepinesshypocretinnarcolepsyneuropharmacologyorexinoveporexton

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Medicine, King Abdulaziz University, Rabigh 25732, Saudi Arabia.
  • Pharmacology and Toxicology Department, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.

ORCID-Profile: Maan H Harbi

Zitieren

APA

Alzahrani, Y. A., & Harbi, M. H. (2026). Orexin-2 Receptor Agonists in Narcolepsy: Restoring the Missing Signal. Journal of Clinical Medicine, 15(21), 8642. https://doi.org/10.3390/jcm15218642

Vancouver

Alzahrani YA, Harbi MH. Orexin-2 Receptor Agonists in Narcolepsy: Restoring the Missing Signal. Journal of Clinical Medicine. 2026;15(21):8642. doi:10.3390/jcm15218642

BibTeX
@article{Alzahrani2026,
  author = {Alzahrani, Yahya A and Harbi, Maan H},
  title = {Orexin-2 Receptor Agonists in Narcolepsy: Restoring the Missing Signal},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {21},
  pages = {8642},
  doi = {10.3390/jcm15218642}
}
Kostenlos starten →